GB201018289D0 - Treatment of respiratory disorders - Google Patents

Treatment of respiratory disorders

Info

Publication number
GB201018289D0
GB201018289D0 GBGB1018289.7A GB201018289A GB201018289D0 GB 201018289 D0 GB201018289 D0 GB 201018289D0 GB 201018289 A GB201018289 A GB 201018289A GB 201018289 D0 GB201018289 D0 GB 201018289D0
Authority
GB
United Kingdom
Prior art keywords
adjuvant
lipid
ibuprofen
treatment
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1018289.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocopea Ltd
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Priority to GBGB1018289.7A priority Critical patent/GB201018289D0/en
Publication of GB201018289D0 publication Critical patent/GB201018289D0/en
Priority to GB1113728.8A priority patent/GB2487808A/en
Priority to RU2013124514/15A priority patent/RU2013124514A/ru
Priority to EP11784752.5A priority patent/EP2632431A1/en
Priority to PCT/GB2011/052115 priority patent/WO2012056251A1/en
Priority to CN2011800637601A priority patent/CN103282021A/zh
Priority to AU2011322255A priority patent/AU2011322255A1/en
Priority to CA2816564A priority patent/CA2816564A1/en
Priority to SG2013033014A priority patent/SG189551A1/en
Priority to JP2013535515A priority patent/JP2013544802A/ja
Priority to MX2013004817A priority patent/MX2013004817A/es
Priority to BR112013010441A priority patent/BR112013010441A2/pt
Priority to US13/365,828 priority patent/US8895537B2/en
Priority to US13/365,824 priority patent/US8895536B2/en
Priority to US14/155,147 priority patent/US10695431B2/en
Priority to US14/155,167 priority patent/US10695432B2/en
Priority to US14/155,080 priority patent/US9265742B2/en
Priority to US14/155,042 priority patent/US9271950B2/en
Priority to US14/155,108 priority patent/US9308213B2/en
Priority to US14/520,150 priority patent/US9381180B2/en
Priority to US14/520,159 priority patent/US9427422B2/en
Priority to US14/520,141 priority patent/US9326958B2/en
Priority to US14/821,687 priority patent/US9744132B2/en
Priority to US14/975,608 priority patent/US9737500B2/en
Priority to US14/975,599 priority patent/US9504664B2/en
Priority to US15/043,327 priority patent/US9750810B2/en
Priority to US15/061,661 priority patent/US9775820B2/en
Priority to US15/169,619 priority patent/US10004704B2/en
Priority to US15/169,617 priority patent/US9693980B2/en
Priority to US15/195,623 priority patent/US9827215B2/en
Priority to US15/195,608 priority patent/US9820952B2/en
Priority to US15/219,245 priority patent/US9789075B2/en
Priority to US15/289,083 priority patent/US20170043016A1/en
Priority to US15/295,933 priority patent/US9795577B2/en
Priority to US15/614,592 priority patent/US10155042B2/en
Priority to US15/684,197 priority patent/US10363232B2/en
Priority to US15/684,214 priority patent/US10213381B2/en
Priority to US15/702,440 priority patent/US10231943B2/en
Priority to US15/794,214 priority patent/US10143671B2/en
Priority to US15/794,178 priority patent/US10188619B2/en
Priority to US15/794,197 priority patent/US10154975B2/en
Priority to US16/012,036 priority patent/US10426748B2/en
Priority to US16/166,272 priority patent/US10596132B2/en
Priority to US16/206,814 priority patent/US10588878B2/en
Priority to US16/206,789 priority patent/US10653778B2/en
Priority to US16/284,221 priority patent/US10835490B2/en
Priority to US16/525,520 priority patent/US10857114B2/en
Priority to US16/573,776 priority patent/US10849869B2/en
Priority to US16/729,363 priority patent/US20200129461A1/en
Priority to US16/818,668 priority patent/US11000493B2/en
Priority to US16/882,667 priority patent/US11224659B2/en
Priority to US16/882,666 priority patent/US11202831B2/en
Priority to US16/882,663 priority patent/US11154500B2/en
Priority to US17/107,724 priority patent/US11660276B2/en
Priority to US17/113,476 priority patent/US11730709B2/en
Priority to US17/146,950 priority patent/US11065218B2/en
Priority to US17/146,989 priority patent/US11103472B2/en
Priority to US17/230,855 priority patent/US11844773B2/en
Priority to US17/378,744 priority patent/US20210338617A1/en
Priority to US17/448,263 priority patent/US11992555B2/en
Priority to US17/540,802 priority patent/US11826428B2/en
Priority to US17/646,241 priority patent/US11918654B2/en
Priority to US18/509,114 priority patent/US20240100002A1/en
Priority to US18/595,716 priority patent/US20240207408A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
GBGB1018289.7A 2010-10-29 2010-10-29 Treatment of respiratory disorders Ceased GB201018289D0 (en)

Priority Applications (64)

Application Number Priority Date Filing Date Title
GBGB1018289.7A GB201018289D0 (en) 2010-10-29 2010-10-29 Treatment of respiratory disorders
GB1113728.8A GB2487808A (en) 2010-10-29 2011-08-10 Oral adjuvant or formulation comprising a lipid and an alcohol
RU2013124514/15A RU2013124514A (ru) 2010-10-29 2011-10-31 Воспалительное заболевание
EP11784752.5A EP2632431A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
PCT/GB2011/052115 WO2012056251A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
CN2011800637601A CN103282021A (zh) 2010-10-29 2011-10-31 炎症性疾病
AU2011322255A AU2011322255A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
CA2816564A CA2816564A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
SG2013033014A SG189551A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
JP2013535515A JP2013544802A (ja) 2010-10-29 2011-10-31 炎症性疾患
MX2013004817A MX2013004817A (es) 2010-10-29 2011-10-31 Enfermedad inflamatoria.
BR112013010441A BR112013010441A2 (pt) 2010-10-29 2011-10-31 doença inflamatória
US13/365,828 US8895537B2 (en) 2010-10-29 2012-02-03 Compositions and methods for treating cardiovascular diseases
US13/365,824 US8895536B2 (en) 2010-10-29 2012-02-03 Compositions and methods for treating chronic inflammation and inflammatory diseases
US14/155,147 US10695431B2 (en) 2010-10-29 2014-01-14 Solid solution compositions and use in cardiovascular disease
US14/155,167 US10695432B2 (en) 2010-10-29 2014-01-14 Solid solution compositions and use in severe pain
US14/155,080 US9265742B2 (en) 2010-10-29 2014-01-14 Compositions and methods for treating inflammatory pain
US14/155,042 US9271950B2 (en) 2010-10-29 2014-01-14 Compositions for treating chronic inflammation and inflammatory diseases
US14/155,108 US9308213B2 (en) 2010-10-29 2014-01-14 Solid solution compositions and use in chronic inflammation
US14/520,150 US9381180B2 (en) 2010-10-29 2014-10-21 Compositions and methods for treating chronic inflammation and inflammatory diseases
US14/520,159 US9427422B2 (en) 2010-10-29 2014-10-21 Compositions for treating cardiovascular diseases
US14/520,141 US9326958B2 (en) 2010-10-29 2014-10-21 Compositions for treating chronic inflammation and inflammatory diseases
US14/821,687 US9744132B2 (en) 2010-10-29 2015-08-07 Solid solution compositions and use in chronic inflammation
US14/975,608 US9737500B2 (en) 2010-10-29 2015-12-18 Compositions and methods for treating severe pain
US14/975,599 US9504664B2 (en) 2010-10-29 2015-12-18 Compositions and methods for treating severe pain
US15/043,327 US9750810B2 (en) 2010-10-29 2016-02-12 Compositions and methods for treating chronic inflammation and inflammatory diseases
US15/061,661 US9775820B2 (en) 2010-10-29 2016-03-04 Solid solution compositions and use in chronic inflammation
US15/169,619 US10004704B2 (en) 2010-10-29 2016-05-31 Compositions and methods for treating chronic inflammation and inflammatory diseases
US15/169,617 US9693980B2 (en) 2010-10-29 2016-05-31 Compositions and methods for treating chronic inflammation and inflammatory diseases
US15/195,623 US9827215B2 (en) 2010-10-29 2016-06-28 Solid solution compositions and use in chronic inflammation
US15/195,608 US9820952B2 (en) 2010-10-29 2016-06-28 Solid solution compositions and use in chronic inflammation
US15/219,245 US9789075B2 (en) 2010-10-29 2016-07-25 Compositions and methods for treating cardiovascular diseases
US15/289,083 US20170043016A1 (en) 2010-10-29 2016-10-07 Solid Solution Compositions and Use in Severe Pain
US15/295,933 US9795577B2 (en) 2010-10-29 2016-10-17 Compositions and methods for treating severe pain
US15/614,592 US10155042B2 (en) 2010-10-29 2017-06-05 Compositions and methods for treating chronic inflammation and inflammatory diseases
US15/684,197 US10363232B2 (en) 2010-10-29 2017-08-23 Compositions and methods for treating severe pain
US15/684,214 US10213381B2 (en) 2010-10-29 2017-08-23 Solid solution compositions and use in chronic inflammation
US15/702,440 US10231943B2 (en) 2010-10-29 2017-09-12 Compositions and methods for treating cardiovascular diseases
US15/794,214 US10143671B2 (en) 2010-10-29 2017-10-26 Solid solution compositions and use in chronic inflammation
US15/794,178 US10188619B2 (en) 2010-10-29 2017-10-26 Solid solution compositions and use in chronic inflammation
US15/794,197 US10154975B2 (en) 2010-10-29 2017-10-26 Solid solution compositions and use in chronic inflammation
US16/012,036 US10426748B2 (en) 2010-10-29 2018-06-19 Compositions and methods for treating chronic inflammation and inflammatory diseases
US16/166,272 US10596132B2 (en) 2010-10-29 2018-10-22 Solid solution compositions and use in chronic inflammation
US16/206,814 US10588878B2 (en) 2010-10-29 2018-11-30 Solid solution compositions and use in chronic inflammation
US16/206,789 US10653778B2 (en) 2010-10-29 2018-11-30 Compositions and methods for treating chronic inflammation and inflammatory diseases
US16/284,221 US10835490B2 (en) 2010-10-29 2019-02-25 Solid solution compositions and use in chronic inflammation
US16/525,520 US10857114B2 (en) 2010-10-29 2019-07-29 Compositions and methods for treating severe pain
US16/573,776 US10849869B2 (en) 2010-10-29 2019-09-17 Compositions and methods for treating chronic inflammation and inflammatory diseases
US16/729,363 US20200129461A1 (en) 2010-10-29 2019-12-28 Compositions Comprising Cancer Drug-Fatty Acid Conjugates
US16/818,668 US11000493B2 (en) 2010-10-29 2020-03-13 Solid solution compositions and use in chronic inflammation
US16/882,667 US11224659B2 (en) 2010-10-29 2020-05-25 Solid solution compositions and use in severe pain
US16/882,666 US11202831B2 (en) 2010-10-29 2020-05-25 Solid solution compositions and use in cardiovascular disease
US16/882,663 US11154500B2 (en) 2010-10-29 2020-05-25 Solid solution compositions and use in chronic inflammation
US17/107,724 US11660276B2 (en) 2010-10-29 2020-11-30 Compositions and methods for treating chronic inflammation and inflammatory diseases
US17/113,476 US11730709B2 (en) 2010-10-29 2020-12-07 Compositions and methods for treating severe pain
US17/146,950 US11065218B2 (en) 2010-10-29 2021-01-12 Compositions and methods for treating chronic inflammation and inflammatory diseases
US17/146,989 US11103472B2 (en) 2010-10-29 2021-01-12 Oral suspensions comprising a non-steroidal anti-inflammatory drug (NSAID)
US17/230,855 US11844773B2 (en) 2010-10-29 2021-04-14 Solid solution compositions and use in chronic inflammation
US17/378,744 US20210338617A1 (en) 2010-10-29 2021-07-18 Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases
US17/448,263 US11992555B2 (en) 2010-10-29 2021-09-21 Solid solution compositions and use in chronic inflammation
US17/540,802 US11826428B2 (en) 2010-10-29 2021-12-02 Solid solution compositions comprising cannabidiols
US17/646,241 US11918654B2 (en) 2010-10-29 2021-12-28 Solid solution compositions and use in severe pain
US18/509,114 US20240100002A1 (en) 2010-10-29 2023-11-14 Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases
US18/595,716 US20240207408A1 (en) 2010-10-29 2024-03-05 Solid Solution Compositions and Use in Severe Pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1018289.7A GB201018289D0 (en) 2010-10-29 2010-10-29 Treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
GB201018289D0 true GB201018289D0 (en) 2010-12-15

Family

ID=43401508

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1018289.7A Ceased GB201018289D0 (en) 2010-10-29 2010-10-29 Treatment of respiratory disorders
GB1113728.8A Withdrawn GB2487808A (en) 2010-10-29 2011-08-10 Oral adjuvant or formulation comprising a lipid and an alcohol

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1113728.8A Withdrawn GB2487808A (en) 2010-10-29 2011-08-10 Oral adjuvant or formulation comprising a lipid and an alcohol

Country Status (11)

Country Link
EP (1) EP2632431A1 (pt)
JP (1) JP2013544802A (pt)
CN (1) CN103282021A (pt)
AU (1) AU2011322255A1 (pt)
BR (1) BR112013010441A2 (pt)
CA (1) CA2816564A1 (pt)
GB (2) GB201018289D0 (pt)
MX (1) MX2013004817A (pt)
RU (1) RU2013124514A (pt)
SG (1) SG189551A1 (pt)
WO (1) WO2012056251A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
JP2014040396A (ja) * 2012-08-23 2014-03-06 Chemo-Sero-Therapeutic Research Institute 脂質異常症治療薬を含有するアジュバント組成物
CN104098686B (zh) * 2013-04-03 2016-03-23 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN103880941B (zh) * 2012-12-21 2016-02-10 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN103880924B (zh) * 2012-12-21 2016-03-23 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CA2897878A1 (en) * 2013-01-14 2014-07-17 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
CN104098685B (zh) * 2013-04-03 2016-03-23 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN104098671A (zh) * 2013-04-03 2014-10-15 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN104098681B (zh) * 2013-04-03 2016-08-10 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
JP2016519108A (ja) * 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
ES2902679T3 (es) * 2013-08-19 2022-03-29 Enzychem Lifesciences Corp Composición que contiene compuesto de monoacetildiacilglicerol como principio activo para prevenir o tratar el asma
US20160199338A1 (en) * 2013-08-19 2016-07-14 Enzychem Lifesciences Corporation Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
CN103932977A (zh) * 2014-04-15 2014-07-23 江苏正大清江制药有限公司 一种塞来昔布制剂的制备方法
CN103893171B (zh) * 2014-04-19 2016-05-25 武汉胜达康生物科技有限公司 盐酸苄达明在制备治疗或预防流感病毒感染药物中的应用
EP3650018B1 (en) * 2017-07-18 2022-09-07 Deyi Pharmarmaceutical Ltd. Application of cannabidiol in treatment of pulmonary hypertension
AU2017429312B2 (en) * 2017-08-31 2022-03-24 Hanyi Bio-Technology Company Ltd. Uses of cannabidiol in preparation of drugs for resisting against influenza
CN109419786B (zh) * 2017-08-31 2021-04-30 汉义生物科技（北京）有限公司 大麻二酚在制备抗流感的药物中的用途
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
TW202138005A (zh) * 2019-12-27 2021-10-16 特定非營利活動法人北東日本研究機構 癌症治療方法及醫藥
CN111214467A (zh) * 2020-03-05 2020-06-02 南京巴傲得生物科技有限公司 吲哚布洛芬在抵抗hmgb1促炎活性中的应用
CN111281973A (zh) * 2020-03-31 2020-06-16 清华大学 含有trpv2激动剂的疫苗佐剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
ES2148345T3 (es) * 1993-10-22 2000-10-16 Hexal Ag Composicion farmaceutica con ciclosporina a, un derivado de vitamina e y un emulsionante.
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
WO2008051186A2 (en) * 2005-08-09 2008-05-02 Nanobio Corporation Nanoemulsion containing compositions having ant i -inflammatory activity
WO2008070950A1 (en) * 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
CA2743551C (en) * 2008-11-19 2017-08-15 Merial Limited Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
JP2014507429A (ja) * 2011-02-04 2014-03-27 バイオコピア リミテッド 心血管疾患の治療のための組成物および方法

Also Published As

Publication number Publication date
MX2013004817A (es) 2013-07-03
JP2013544802A (ja) 2013-12-19
GB201113728D0 (en) 2011-09-21
AU2011322255A1 (en) 2013-05-23
RU2013124514A (ru) 2014-12-10
GB2487808A (en) 2012-08-08
SG189551A1 (en) 2013-06-28
EP2632431A1 (en) 2013-09-04
WO2012056251A1 (en) 2012-05-03
CA2816564A1 (en) 2012-05-03
BR112013010441A2 (pt) 2016-08-09
CN103282021A (zh) 2013-09-04

Similar Documents

Publication Publication Date Title
GB201018289D0 (en) Treatment of respiratory disorders
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
WO2011139684A3 (en) Nicotine-containing pharmaceutical compositions
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
NZ598654A (en) Immunogenic compositions including tlr activity modulators
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
GB0814302D0 (en) Compounds and methods
BR112015026418A2 (pt) formulação de liberação prolongada da colchicina como ingrediente ativo, método para o tratamento e/ou prevenção de uma doença cardiovascular ou uma doença inflamatória em um indivíduo, processo de preparação de um comprimido de liberação prolongada da colchicina e composição terapêutica de liberação prolongada moldada e comprimida compreendendo a colchicina e excipientes combinados em uma matriz
MX354423B (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
AR084865A1 (es) Preparacion de desintegracion rapida, comprimido dispersable por via oral
RU2013144383A (ru) Лекарственная форма и применение диэтилстильбестрола для лечения рака предстательной железы или молочной железы
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
TN2015000135A1 (en) Modified release formulations for oprozomib
UY32109A (es) Métodos para utilizar composiciones de liberación sostenida de aminopiridina
TR201821157T4 (tr) İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m.
MX2013012206A (es) Metodo para producir substancias con gas sobresaturado,dispositivo de suministro transdermico de las mismas, y usos de las mismas.
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
MX2009012713A (es) Nuevos derivados de acido 3-fenil acrilico de receptores de tipo ppar, su metodo de preparacion y su uso en composiciones cosmeticas o farmaceuticas.
MX2023002649A (es) Nueva formulacion de acido gamma-aminobutirico.
MX2013012204A (es) Metodo para producir substancias con gas sobresaturado, dispositivo de suministro transdermico de las mismas, y usos de las mismas.
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
MX2009003770A (es) Formulaciones de oximorfona robustas, de liberacion sostenida y metodos para su uso.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)